TAT 2015 will be organised according to the proven standards, developed in the course of the twelve previous TAT Congresses. TAT 2015 will therefore offer the latest on new molecular and immunological targets and agents for innovative cancer therapies, in particular the most promising ones in early-phase clinical development in a confined setting with only plenary sessions. Owing to its medium size, TAT 2015 offers excellent opportunities for networking with the world’s leaders in oncology phase 1 studies from academia and industry.
The near-final scientific agenda and the first list of confirmed faculty are now online on the congress web site.
Abstract submission for TAT 2015 is now open and will remain open until December 31, CET.
